

Special Issue

The Interleukin-6 Family in Disease Pathogenesis and Therapy

Message from the Guest Editors

The IL-6 family is a group of closely related pleiotropic cytokines produced by a variety of cells in response to inflammatory stimuli. They are related in structure and function and include IL-6, IL-11, leukemia inhibitory factor (LIF), Oncostatin M (OSM), IL-27, IL-31, etc. The actions of these cytokines are mediated through specific cell surface receptors and the shared signal transducing subunit, gp130. Subsequent signalling is mediated through a tight reciprocal regulation of either ERK-MAPK or JAK-STAT pathways, critical for the generation of physiological responses to IL6-family cytokines. Conversely, disturbance of this finely orchestrated signalling, leads to pathological responses. The IL-6 family stimulates the inflammatory and autoimmune processes in many diseases. Hence, there is a strong interest in developing agents against these molecules or their signalling pathways to treat disease. Articles (original and reviews) are being sought for a Special Issue highlighting the importance of the IL-6 family of cytokines in both health and disease and novel approaches to modulate their function.

Guest Editors

Dr. Steven E. Mutsaers

Institute for Respiratory Health, University of Western Australia, Perth, Australia

Prof. Cecilia M. Prêle

Institute for Respiratory Health and University of Western Australia, Perth, Australia

Deadline for manuscript submissions

closed (30 September 2020)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/22116

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).